CA2366059A1 - Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer - Google Patents
Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer Download PDFInfo
- Publication number
- CA2366059A1 CA2366059A1 CA002366059A CA2366059A CA2366059A1 CA 2366059 A1 CA2366059 A1 CA 2366059A1 CA 002366059 A CA002366059 A CA 002366059A CA 2366059 A CA2366059 A CA 2366059A CA 2366059 A1 CA2366059 A1 CA 2366059A1
- Authority
- CA
- Canada
- Prior art keywords
- mage
- glu
- seq
- leu
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des molécules d'ADN complémentaire isolées et déterminées grâce à une méthode élaborée pour faciliter le niveau d'expression génique. L'invention concerne également des protéines et des peptides obtenus sur la base de ces molécules d'ADN complémentaire, ainsi que différentes utilisations diagnostiques et thérapeutiques de ces matières.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26097899A | 1999-03-02 | 1999-03-02 | |
| US09/260,978 | 1999-03-02 | ||
| PCT/US2000/005346 WO2000052163A1 (fr) | 1999-03-02 | 2000-03-01 | Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2366059A1 true CA2366059A1 (fr) | 2000-09-08 |
Family
ID=22991462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002366059A Abandoned CA2366059A1 (fr) | 1999-03-02 | 2000-03-01 | Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1194542A1 (fr) |
| JP (1) | JP2003512814A (fr) |
| KR (1) | KR20020011967A (fr) |
| AU (1) | AU3389500A (fr) |
| CA (1) | CA2366059A1 (fr) |
| NZ (1) | NZ513739A (fr) |
| WO (1) | WO2000052163A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE545708T1 (de) * | 2005-11-14 | 2012-03-15 | Univ Laval | Krebsantigen mage-a9 und verwendungen davon |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| WO2019007974A1 (fr) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc, le cppc et d'autres cancers |
| KR20200026898A (ko) | 2017-07-07 | 2020-03-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| WO2025242815A1 (fr) * | 2024-05-23 | 2025-11-27 | CureVac SE | Immunothérapie d'un carcinome à cellules squameuses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| US5612201A (en) * | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
-
2000
- 2000-03-01 CA CA002366059A patent/CA2366059A1/fr not_active Abandoned
- 2000-03-01 KR KR1020017011090A patent/KR20020011967A/ko not_active Withdrawn
- 2000-03-01 EP EP00912112A patent/EP1194542A1/fr not_active Withdrawn
- 2000-03-01 WO PCT/US2000/005346 patent/WO2000052163A1/fr not_active Ceased
- 2000-03-01 NZ NZ513739A patent/NZ513739A/xx not_active Application Discontinuation
- 2000-03-01 AU AU33895/00A patent/AU3389500A/en not_active Abandoned
- 2000-03-01 JP JP2000602775A patent/JP2003512814A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ513739A (en) | 2001-09-28 |
| KR20020011967A (ko) | 2002-02-09 |
| AU3389500A (en) | 2000-09-21 |
| JP2003512814A (ja) | 2003-04-08 |
| WO2000052163A1 (fr) | 2000-09-08 |
| EP1194542A1 (fr) | 2002-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100306464B1 (ko) | Mhc분자hla-c-클론10과복합체를형성하는분리된펩티드및그것의사용 | |
| CN1072719C (zh) | 可分离的编码肿瘤排斥抗原前体的核酸序列 | |
| US6517837B1 (en) | Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer | |
| Zarour et al. | The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100 | |
| KR20010053180A (ko) | 시클로필린 b 유래의 종양 항원 펩티드 | |
| US6555652B1 (en) | Tumor antigen peptide derivatives | |
| US20120123090A1 (en) | Novel tumor antigen protein sart-3 and tumor antigen peptides thereof | |
| US6605711B1 (en) | NY-ESO-1 peptide derivatives, and uses thereof | |
| CN1059466C (zh) | 鉴定患有细胞异常性的个体的方法 | |
| CA2265449A1 (fr) | Tyrosine phosphatases proteiques associees a des maladies | |
| EP1230261B1 (fr) | Derives peptidiques de ny-eso-1 et leurs applications | |
| US20030180739A1 (en) | Reagents and methods for identifying gene targets for treating cancer | |
| JP2003000270A (ja) | 腫瘍抗原 | |
| CA2386029A1 (fr) | P-glycoproteines provenant de <i>macaca fascicularis</i> et utilisations correspondantes | |
| JP4190291B2 (ja) | 癌細胞の増殖を調節するのに有用なポリヌクレオチド | |
| AU3389500A (en) | Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer | |
| US5837476A (en) | Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor | |
| CN100393745C (zh) | 一种肿瘤抗原蛋白质和肿瘤抗原肽 | |
| CA2319668C (fr) | Genes humains tsc403 et ing1l | |
| CA2384981A1 (fr) | Glycoproteines p et leurs utilisations | |
| CA2165435C (fr) | Nouveaux precurseurs d'antigenes pour le rejet des tumeurs et molecules d'acides nucleiques codant pour ces precurseurs | |
| CN100393746C (zh) | 一种肿瘤抗原蛋白质和肿瘤抗原肽 | |
| US7270980B2 (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
| HK1037672A (en) | Novel tumor antigen protein sart-3 and tumor antigen peptide thereof | |
| AU2313401A (en) | Novel human myeloid terminal differentiation response gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |